BraindumpEnter Title
*Pharmacological Group*
*A. BOLUS*
1. Short-acting regular human insulin: E.g
- Actrapid®
- Insuman®R
2. Rapid-acting analogue insulin:
a. Aspart (Novorapid®)
b. Lispro (Humalog®)
c. Glulisine (Apidra®)
*B. BASAL*
1. Intermediate-acting or NPH insulin: E.g
- Insulatard®N
- Insuman®N
2. Long-acting analogue insulin:
a. Glargine U100 (Basalog®, Lantus® Solostar)
b. Detemir (Levemir®)
c. Glargine U300 (Toujeo® Solostar)
d. Degludec (Tresiba®)
*C. PREMIXED*
1. Premixed human insulin:
a. (30% regular insulin + 70% NPH):
- Mixtard®30
- Insuman®30/70
2. Premixed analogue insulin:
a. 30% insulin aspart + 70% insulin aspart protamine (Novomix®30)
b. 25% insulin lispro + 75% insulin lispro protamine (HumalogMix®25™)
c. 50% insulin lispro + 50% insulin lispro protamine (HumalogMix®50™)
*D. CO-FORMULATION*
1. 70% insulin degludec + 30% insulin aspart: iDegAsp (Ryzodeg® 70/30)
2. Insulin glargine + lixisenatide (Soliqua™)
---
*Indications and Dosage*
*A. Bolus insulin*
- administered pre-meal due to its short or rapid onset of action. It is used to control the post-meal glucose excursion and can be used with an insulin pump
*B. Basal insulin*
- administered once or twice daily due to its intermediate or long-acting profile. It covers the basal insulin requirements between meals and overnight secondary to endogenous hepatic glucose production.
*C. Premixed insulin*
- biphasic insulin incorporating a combination of short or rapid-acting insulin with its intermediate acting counterpart into a single formulation. It covers both post-prandial glucose excursions as well as basal insulin requirements simultaneously
*D. Co-formulation insulin*
- a combination of two types of insulin or insulin with a glucagon like peptide-1 receptor analogue (GLP1-RA) such as:
---